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PRC2 inhibition counteracts 
the culture-associated loss of 
engraftment potential of human 
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Linda Varagnolo1, Qiong Lin2, Nadine Obier3, Christoph Plass4, Johannes Dietl5, 
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Cord blood hematopoietic stem cells (CB-HSCs) are an outstanding source for transplantation 
approaches. However, the amount of cells per donor is limited and culture expansion of CB-HSCs 
is accompanied by a loss of engraftment potential. In order to analyze the molecular mechanisms 
leading to this impaired potential we profiled global and local epigenotypes during the expansion 
of human CB hematopoietic stem and progenitor cells (HPSCs). Human CB-derived CD34+ cells 
were cultured in serum-free medium together with SCF, TPO, FGF, with or without Igfbp2 and 
Angptl5 (STF/STFIA cocktails). As compared to the STF cocktail, the STFIA cocktail maintains 
in vivo repopulation capacity of cultured CD34+ cells. Upon expansion, CD34+ cells genome-wide 
remodel their epigenotype and depending on the cytokine cocktail, cells show different H3K4me3 
and H3K27me3 levels. Expanding cells without Igfbp2 and Angptl5 leads to higher global H3K27me3 
levels. ChIPseq analyses reveal a cytokine cocktail-dependent redistribution of H3K27me3 profiles. 
Inhibition of the PRC2 component EZH2 counteracts the culture-associated loss of NOD scid gamma 
(NSG) engraftment potential. Collectively, our data reveal chromatin dynamics that underlie the 
culture-associated loss of engraftment potential. We identify PRC2 component EZH2 as being 
involved in the loss of engraftment potential during the in vitro expansion of HPSCs.
Hematopoietic stem cells (HSCs) are a rare cell type that are essential for life-long blood production. 
The transplantation of HSCs has evolved from a highly experimental procedure to a standard therapy 
for several malignant and non-malignant hematologic and other diseases1. Today, most HSC transplant 
samples are isolated from peripheral blood after mobilization or from bone marrow (BM) aspirates of 
healthy donors. Cord blood (CB)-derived HSCs are a third source of HSCs for patients with hematologic 
disorders and metabolic storage diseases2. CB-HSC transplantation is increasingly used because of its 
availability, banking features and lower incidence of severe chronic graft-versus-host disease (GvHD) 
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leading to reduced HLA-requirement compared to BM cells. However, limited cell numbers per isolate 
restrict CB transplantation. Despite optimization of isolation and processing techniques, the low cell 
numbers per isolate and the inability to robustly expand CB-HSCs renders insufficient stem cell numbers 
a major constraint in many transplantation settings. One approach to overcome the low cell content of 
single CB units is co-transplantation of two units3.
A multitude of cell-intrinsic and extrinsic self-renewal factors and combinations thereof in addition 
to stromal cell cultures were assessed for their ability to robustly expand HSCs4,5. Proliferation of HSCs 
could be achieved by in vitro cultures but often stem cell properties such as longterm and multlineage 
engraftment were lost. While transcriptome studies of HSCs did so far not lead to novel concepts of 
HSC expansion6,7, other studies explored the cytokine profile of murine HSC supporter cells and the 
HSC receptor status in fetal liver, the developmental stage and physiological side of high HSC expan-
sion8. This approach introduced Insulin-like growth factor-binding protein 2 (Igfbp2) and a group of 
angiopoietin-like (Angptl) proteins, secreted glycoproteins consisting of seven members, as alternative 
growth factors for HSCs expansion9.
The self-renewal and differentiation of HSCs is linked to interconnected transcriptional and epige-
netic circuits, both triggered by extra- and intracellular signals10. Epigenetic mechanisms directly shape 
and progressively restrict the lineage potential of HSCs by controlling chromatin compaction and acces-
sibility11,12. Particularly, the evolutionary conserved Polycomb-group (PcG) and Trithorax-group (trxG) 
proteins play pivotal roles in the regulation of HSC function13,14. Both act as multifactorial complexes that 
influence gene expression by adding specific modifications to histone tails. While the Polycomb repres-
sive complex (PRC) 2 silences genes by tri-methylation of histone H3 lysine 27 (H3K27), trxG proteins 
act antagonistically via the generation of H3K4me3 marks15. The simultaneous marking of genes with 
activating H3K4me3 and repressive H3K27me3 modifications (bivalent domains) poises chromatin for 
activation16. Remodelling of the bivalent landscape accompanies the differentiation of HSCs12,17,18. Maps 
of the epigenetic landscapes of HSCs and differentiated progeny revealed that combinatorial modification 
patterns ensure cooperative regulation of transcription supporting the notion that epigenetics accompa-
nies HSC function and differentiation17. This notion is increasingly translated into practice as epigenetic 
strategies are considered for HSC expansion and as treatment option of hematopoietic malignancies19-21.
While high-resolution and genome-wide histone modification maps of fresh mouse and human HSCs 
were described12,17,22, it largely remains open how ex vivo culture conditions influence chromatin mod-
ifications of HSCs. Upon culture expansion of human CB-CD34+ hematopoietic progenitor/stem cells 
(HPSCs) were shown to acquire DNA-hypermethylation at specific sites in the genome23,24.
Here, we assessed epigenetic changes in fresh and culture-expanded CB-HPSCs. We aimed at iden-
tifying epigenetic target mechanisms associated with ex vivo expansion. In summary, we show that cul-
ture expansion induced global and local changes of H3K4me3 and H3K27me3 profiles. We detected 
widespread variations of global H3K27me3 levels and genome-wide redistribution that are connected to 
elevated expression of the PRC2 component EZH2. Inhibition by EZH2 inhibitor treatment increased 
engraftment potential of cultured HPSCs.
Materials and Methods
Isolation and culture of CB-derived hematopoietic progenitor/stem cells. Human CB cells 
were isolated from fresh CB samples obtained from the Department for Gynecology and Obstetrics, 
University Clinic Würzburg, after written consent according to the guidelines specifically approved by 
the Ethic Committee of the Medical Faculty of the University of Würzburg, Germany (Permit Number: 
185/08). CD34+ progenitors were obtained using a CD34 progenitor cell isolation kit (Miltenyi Biotec). 
The purities of CD34+ samples were determined via flow cytometry. Immunophenotype of CD34+ 
cells were: 91% CD34+ ; 86.9% CD133+ ; 33% CD38+ ; 98% CD45+ ; immunophenotype of CD34− 
cells were: 1% CD34+ ; 1.2% CD133+ ; 46.8% CD38+ ; 58% CD45+ . For expansion, CD34+ progenitor 
cells were seeded at a concentration of 2 × 105 cells/ml into StemSpan serum-free medium (StemCell 
Technologies Inc.) supplemented with 1% penicillin, streptomycin (Gibco Invitrogen Corporation), hep-
arin (10 ng/mL, Ratiopharm) plus either STF (stem cell factor (SCF, 10 ng/mL, Peprotech), recombinant 
human thrombopoetin (TPO, 20 ng/mL, Peprotech), recombinant human fibroblast growth factor-1 
(FGF-1, 10 ng/mL, Peprotech)), or STFIA (STF plus angiopoietin like-5 (Angptl-5, 500 ng/mL, Tebu-Bio) 
and insulin-like growth factor binding-protein 2 (IGFBP2, 100 ng/mL, R&D Systems)) cocktails9. CD34+ 
cells in STF culture were co-incubated with either GSK343 (SGC, University of Toronto) or GSK126 
EZH2 inhibitors (Chemie Tek) at 1 mM.
NSG transplantation. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were bred and maintained 
at the ZEMM (University Würzburg, Germany). All animals handling was done according to the ani-
mal protection guidelines of the government of Unterfranken, Germany. Fresh or expanded cells were 
injected intravenously into sub-lethally irradiated (1.5 Gy, Faxitron CP-160 X-ray radiation cabinet 
(160 kV, 6.3 mA, 0.4 Gray/min, filter: 0.5 mm Cu)) 8–10 weeks old female NSG recipients. 0.5 × 105 fresh 
CD34+ cells together with 105 NSG spenocytes were injected per recipient. The progeny of 2 × 105 
CD34+ cells (injected cell numbers per animal ranged from 0.4–1 × 106 cells) expanded in STF or STFIA 
cultures were equally split and injected into 4 recipients. Multilineage engraftment was analyzed by stain-
ing peripheral blood, splenocytes and BM of recipients with human antibodies specific for CD45, CD19, 
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CD14, CD3 or CD34 or with matched isotype controls (Miltenyi Biotec). Secondary transplantations 
were carried out at 16 weeks post-primary transplantation. The BM cells of both tibias and femurs of 
primary recipients were injected into two sub-lethally irradiated secondary recipients.
Flow cytometry and chromatin flow cytometry. Cells were incubated with FITC- or PE-labeled 
CD45− , CD34− , CD133− , CD38− , CD14− , CD19− , CD3-specific and matching isotype antibod-
ies (Miltenyi Biotec). For chromatin flow cytometry25, cells were added dropwise into tubes contain-
ing 1 ml ice-cold 88% MeOH/PBS for 30 minutes. Primary antibodies (H3K4me3 (Abcam), H3K27me3 
(Diagenode), H3K79me3 (Abcam) and H3K9me3 (Upstate)) were added and samples were incubated 
(1 h, 4 °C). For normalization, cells were stained with an H3-specific antibody (Abcam). Cells were ana-
lyzed using a FACS Canto machine (BD) running FACS Diva software (BD).
Western blot analyses. Protein samples were prepared and blotted onto nitrocellulose mem-
branes after blocking unspecific binding sites. Membranes were incubated at 4 °C over night with pri-
mary antibodies (anti-H3K4me3 (Abcam), anti-H3K27me3 (Diagenode), anti-H3 (Abcam), anti-EZH2 
(Diagenode)). Following 3 washes, membranes were incubated (2 h, RT) with secondary HRP-coupled 
antibodies, before proteins were detected by ECL addition (ECL, Amersham Biosciences) and chemilu-
minescence measurement.
ChIPseq analyses. ChIPseq analyses were conducted as replicates, merged and analyzed fol-
lowing guidelines and recommendations of the ENCODE consortium26. For detailed description see 
Supplemental Material.
Statistical analysis. Results are indicated with standard error of the average of independent experi-
ments. Analyses were done by two-tailed Student t-test. Probability value of p < 0.05 denoted statistical 
significance.
Results
Expansion of CD34+ cells is accompanied by global histone modification changes. We 
sought to determine whether and how the expansion of CB-HPSCs genome-wide alters histone modifi-
cations and remodels global and local chromatin states. First, functional characterization of CD34+ cells 
cultured under different cytokine cocktail conditions confirmed the increased multilineage engraftment 
potential in primary and secondary NSG recipients in STFIA- versus STF-cultured CB CD34+ cells 
(Fig.  1A, Fig. S1)9. Notably, the CD34+ fraction is heterogeneous and only a small subset resembles 
hematopoietic stem cells (HSCs). Global gene expression analyses of STF- versus STFIA-cultured CD34+ 
cells and cluster analysis indicated no statistically significant differences between STF and STFIA samples 
(p-value < 0.05 and fold change > 2) and that samples from one donor clustered together (Fig. S2A). 
This is underlined by the heatmaps of differentially expressed genes that revealed only minor transcrip-
tomic changes between STF- versus STFIA-cultured CD34+ samples while gene expression between 
fresh and expanded CD34+ cells differed (Fig. S2B). Genes that were down-regulated upon STF or 
STFIA expansion belonged to Gene Ontology (GO) categories ‘regulation of transcription’ and ‘cell death’, 
while genes that were up-regulated during culture were enriched for GO terms associated with cell cycle 
regulation (Table S3, Fig. S3). To assess culture-induced global epigenetic changes we used Western blot 
and intranuclear flow cytometry25. Both analyses revealed higher levels of the activating H3K4me3 and 
the repressive H3K27me3 modifications in fresh CD34+ compared to CD34− cells. Upon expansion 
of CD34+ cells, we noticed that global H3K4me3 levels did not differ significantly between STF and 
STFIA cultures whereas STFIA-cultured cells carried less H3K27me3 than fresh CD34+ or STF-cultured 
CD34+ cells (Fig. 1B,C). Despite similarities in gene expression between the two different culture con-
ditions, just the STFIA-cultured cells showed elevated repopulation potential. Together this shows that 
changes in H3K27me3 levels but less changes in H3K4me3 levels accompany the culture-associated loss 
of engraftment potential.
Redistribution of K4 and K27 tri-methylation marks upon culture of CD34+ cells. To char-
acterize the impact of in vitro expansion on chromatin signatures in greater detail, we performed 
H3K4me3- and H3K27me3-specific chromatin immunoprecipitation and next generation sequencing 
(ChIPseq) and mapped histone modifications associated with active and repressed transcriptional states 
on a genome-wide level. Procedures were optimized for low cell numbers27. Typically 80,000 cells were 
used for ChIPseq analysis. Following the experimental standards as set by the ENCODE consortium, 
replicates were processed independently and merged for subsequent data analysis, as the number of 
ChIPseq detected sites typically increases with the number of sequencing reads and, particularly, weaker 
sites can be detected with greater confidence in deeper data sets because of the increased statistical 
power28. Raw data processing and quality control revealed high replicate correlations between individual 
samples according to ENCODE ChIPseq guidelines (Fig. S4)26. To assess similarities between individual 
samples, we firstly performed unsupervised hierarchical clustering of complete data sets comprising the 
entire genome partitioned into 500 bp bins. This clustering using Ward’s minimum variance method 
revealed that H3K4me3 samples showed a closer relationship between the datasets of the two expanded 
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Figure 1. Engraftment activities and global H3K27me3 and of H3K4me3 levels in fresh and expanded 
CD34+ cells. A) Shown are percentages of human chimerism by CD45-specific flow cytometry in the bone 
marrow of NOD-scid IL2Rγ null (NSG) transplant recipients. After 7 days of culture the progeny of 2 × 105 
CD34+ cells in STF- or STFIA-supplemented cultures were equally split and injected into 4 recipients. 
Recipients injected with 0.5 × 105 fresh CD34+ cells are shown as controls. Each symbol represents the 
engraftment of a single recipient (left). Also shown are percentages of human chimerism in the bone marrow 
of mice following transplantation of bone marrow cells from primary into secondary recipients (right). The 
bone marrow of one primary was injected into two secondary recipients. Recipients were analyzed 8 weeks 
post transplant. Student t-test, ***p < 0.001, *p < 0.05 n = 3. B) Representative H3K4me3- and H3K27me3-
specific Western blot analysis of fresh CD34− and CD34+ cells, and of CD34+ cells expanded for 7 days 
with either STF or STFIA cocktails (left). Relative signal intensities of bands were quantified (middle, right). 
n = 4. Student t-test, **p < 0.01, *p < 0.05. C) Summary of H3-normalized values of global H3K4me3 and 
H3K27me3 fluorescence levels of fresh CD34− and CD34+ cells, and of CD34+ cells expanded for 7 days 
with either STF or STFIA cocktails analyzed via chromatin flow cytometry, *p < 0.05, n = 4.
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compared to fresh cells (Fig. 2A). In contrast, the H3K27me3 samples of STF- and STFIA-cultured and 
fresh CD34+ cells grouped together while the CD34− sample separated. A closer inspection revealed 
that H3K4me3 meta-profiles on all promoters and gene bodies were maintained during expansion of 
CD34+ cells, independently of cocktail composition while fresh CD34− cells exhibited a slightly higher 
ChIPseq read density (Fig. S5A). Upon expansion of CD34+ cells, H3K27me3 levels at transcriptional 
start sites and within gene bodies decreased.
We then used peak detection to identify regions of significant H3K4me3 and H3K27me3 enrichment. 
Overall, we noticed that larger portions of the genome were enriched with H3K27me3 compared to 
H3K4me3 marks (Fig. S5B). The genome fraction covered by H3K4me3 enrichment (peaks) was larger in 
STFIA- and STF-cultured CD34+ as compared to fresh cells. In contrast, the genome fraction covered by 
H3K27me3 peaks was increased upon STFIA- but not STF-culturing. Peak counts of H3K27me3-marked 
regions in STF cells were reduced compared to other samples. Analyzing the size of H3K4me3- and 
H3K27me3-enriched regions (islands, horizontal expansion) we observed that H3K4me3 regions in 
fresh CD34− and CD34+ cells were similarly sized, while STF or STFIA culture increased the size of 
H3K4me3-marked regions (Fig.  2B). In parallel with the reduced peak counts of H3K27me3-marked 
regions in STF-cultured cells, H3K27me3-enriched regions were considerably broadened in STF-cultured 
cells similar to fresh CD34− cells.
Genome-wide analysis of H3K4me3 and H3K27me3 peak distribution over functional genomic ele-
ments revealed that promoters, introns and intergenic regions were preferentially H3K4me3-marked. In 
contrast, H3K27me3 was widely deposited at introns and intergenic regions (Fig. 2C). Upon expansion of 
CD34+ cells, promoters lost and introns gained H3K4me3. Culture conditions had no visible qualitative 
or quantitative impact on the lawn of H3K27me3 marking at the analyzed elements.
Next, we asked if the average profiles of the H3K4me3 and the H3K27me3 marks differ at the tran-
scriptional start sites of those 2,000 genes which are expressed highest and lowest in fresh CD34+ cells 
(Fig. S6A). The analysis revealed a typical distribution of H3K4me3 with a nucleosome gap at the tran-
scriptional start site and almost complete lack of H3K27me3 on active promoters for the highly expressed 
genes. For these 2,000 genes highest expressed in CD34+ cells, STFIA-cultured CD34+ cells exhibited 
an almost identical H3K4me3 promoter profile as fresh CD34+ cells, whereas STF-cultured CD34+ cells 
and CD34− cells had higher and lower tag density, respectively. Correspondingly, the lowest expressed 
genes carried almost no H3K4me3 and more repressive H3K27me3 marks in all 4 samples (Fig. S6B).
Previously, Cui et al. reported broad changes of H3K4me3 and H3K27me3 patterns in homeobox 
(Hox) gene clusters during CB-HSC differentiation17. Therefore we assessed whether culture of CD34+ 
cells is paralleled by changes in H3K4me3 and H3K27me3 marking in the HoxA and HoxB clusters 
(Fig. 3A). Overall we noticed differences in H3K27me3 deposition at the HoxA and HoxB loci between 
fresh CD34+ and CD34− cells but little changes between the culture conditions. Less differences in 
H3K4me3 were visible between fresh and cultured cells. Overall, expansion of CD34+ cells maintained 
the distribution of H3K4me3 and H3K27me3 patterns in HoxA and HoxB loci as seen in fresh cells 
with only minor differences (i.e. in HoxA5 - A9 regions). H3K4me3- and H3K27me3-specific ChIP for 
selected promoter regions of development- and HPSC-specific genes were employed for further char-
acterization of ChIP-seq profiles (Fig.  3B). Overall it appears that the distribution of H3K4me3 and 
H3K27me3 in ChIPseq marks was consistant with ChIP-PCR analysis in promoter regions and corre-
sponded to the transcriptional states of the selected genes. Depending on the locus, H3K27me3 patterns 
changed between the two culture conditions more than H3K4me3 patterns. For example, in the CD34 
gene body, STF-cultured cells showed higher enrichment of H3K27me3 compared to STFIA cells while 
H3K4me3 patterns were similar.
A closer look at H3K4me3- or H3K27me3-enriched promoters revealed that culture conditions 
changed the set of enriched promoters in an individual way (Fig.  4A, Table S1). One third of all pro-
moters enriched with either H3K4me3 or H3K27me3 were exclusively marked depending on whether 
fresh, STF- or STFIA-cultured cells were analyzed. GO analysis of H3K4me3-enriched promoters mostly 
revealed functional categories of ‘transcriptional regulation’ and ‘metabolic processes’ in fresh and 
STFIA-expanded CD34+ cells while STF-expanded cells associated with ‘signaling’ and ‘cell death’ (Fig. 
S7). The H3K27me3-enriched promoters were associated with the GO-terms ‘signal transduction’ and 
‘differentiation’ in fresh and cultured samples.
To assess the relation between chromatin modification changes and altered gene expression, we 
ranked 26,000 genes according to the fold-change of H3K4me3 or H3K27me3 sequencing reads in 
their promoter regions and asked for changes in gene expression. In a direct comparison of STFIA 
versus STF culture conditions, we noticed more H3K4me3 losses than gains (Fig. 4B). While H3K4me3 
changes appeared to be more balanced with similar extent of lossed and gained areas, the extent of 
H3K27me3 changes was higher compared to H3K4me3 changes (as indicated by the enlarged saturated 
red and blue areas). The greater extent of H3K27me3 changes compared to H3K4me3 was also shown 
by the larger area below the line plot of H3K27me3 (Fig. S8A). This indicates a higher remodelling 
of H3K27me3-enriched promoters compared to H3K4me3 promoters without transcriptomic changes. 
Under both culture conditions, gain of H3K27me3 at promoter regions was more frequent than loss 
when compared to fresh CD34+ cells (Fig. S8B, C). In contrast, H3K4me3 changes were almost balanced 
in STFIA-cultured CD34+ cells whereas H3K4me3 gain was predominant upon STF culture compared 
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Figure 2. Genome-wide distribution of H3K4me3 and H3K27me3 profiles in fresh and expanded 
CD34+ cells. A) Unsupervised hierarchical cluster analysis using Ward’s minimum variance of H3K4 and 
H3K27 trimethylation ChIPseq data sets originating from fresh CD34− and CD34+ cells, and from CD34+ 
cells expanded for 7 days with either STF or STFIA cocktails. Data sets of two independent experiments 
per sample were merged. The entire sequenced genome was partitioned in 500 bp bins. B) H3K4me3 and 
H3K27me3 peak size distributions in fresh CD34− and CD34+ cells, and in CD34+ cells expanded for 
7 days with either STF or STFIA cocktails using kernel density graphs. Peaks were called using the using 
SICER V1.1. C) Genome-wide distribution of H3K4me3 and H3K27me3 histone modifications. Shown are 
percentages of peaks in promoter, 5′ UTR, exon, intron, 3′ UTR, TSS, intergenic and non-intergenic regions.
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Figure 3. Culture-induced histone modification changes. A) Shown are H3K4me3- and H3K27me3 
profiles in the HoxA (chr7:27,132,263 – 27,246,155) and HoxB (chr17:46,606,551 – 46,703,627) loci in fresh 
CD34− and CD34+ cells, and in CD34+ cells expanded for 7 days with either STF or STFIA cocktails. 
Data are displayed using the Integrative Genomics Viewer software. The positions of HoxA and HoxB genes 
are indicated. On the y-axis the number of reads per 200 bp windows are displayed. The position of introns, 
exons and the direction of transcription are shown. B) ChIP-seq profiles, ChIP-PCR and RT-PCR analyses 
of selected genes in fresh CD34− and CD34+ cells and in STF- and STFIA-expanded cells. The TSS and 
the amplicon location relative to the TSS are indicated. Sizes of entire loci were: CD34, 31 kb; LMO2, 37 kb; 
TAL1, 17 kb; RUNX1, 95 kb.
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to fresh CD34+ cells. For neither culture condition we observed a correlation between H3K4me3 or 
H3K27me3 changes and gene expression.
Finally, we looked at the number of promoters with both H3K4me3 and H3K27me3 marks and 
noticed that fresh CD34+ and STF- or STFIA-cultured cells showed twice the numbers of promoters 
with the bivalent mark compared to CD34− cells (Fig.  5A). To assess the dynamics of co-occupancy 
resolution upon expansion we constructed maps of promoter bivalency status of fresh and cultured 
cells (Fig. 5B). Only about one third of the genes marked with both modifications in fresh CD34+ cells 
maintained the bivalent mark upon STF or STFIA expansion. GO analysis revealed enrichment of genes 
belonging to blood vessel development and morphogenesis in STFIA samples (Fig. S9, Table S2). Overall, 
we observed a cocktail-specific reorganization of the bivalency status.
Figure 4. Analysis of promoters enriched for H3K4me3 or H3K27me3. A) Venn diagrams show numbers 
of promoters marked with either H3K4me3 or H3K27me3 in fresh CD34+ cells, and in CD34+ cells 
expanded for 7 days with either STF or STFIA cocktails. (n = 2). B) Approximately 26,000 transcripts taken 
from the Affymetrix expression arrays of STFIA- and STF-cultured CD34 + cells were ranked according to 
the log2-fold change (STFIA versus STF) of sequencing reads in their promoter regions (defined as –1000 bp 
to + 500 bp around transcriptional start site). Log2-fold changes ranged from –3.84 to 4.02 for H3K4me3 
and –4.19 to 3.51 for H3K27me3 and were displayed by color coding (shades of red = positive log2-fold 
changes, grey = no change/0, blue = negative log2-fold changes). The same representation was chosen for 
the log2-fold changed mRNA expression values for the respective transcripts taken from the Affymetric 
expression arrays (lane labelled ‚RNA’).
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EZH2 inhibition increases engrafting potential of cultured CD34+ cells. Our analyses revealed 
a culture-associated increase and a genome-wide redistribution of H3K27me3 marks. We therefore 
assessed the EZH2 protein expression in fresh and expanded CD34+ cells. EZH2 is the protein with 
the enzymatic activity of PRC2 that catalyzes the H3K27me3 mark29. qRT PCR and Western blotting 
showed higher expression of EZH2 in fresh CD34+ compared to CD34− cells and elevated EZH2 lev-
els in STF- compared to STFIA-cultured cells (Fig.  6A, Fig. S10). ChIPseq analyses of the EZH2 locus 
revealed H3K4me3 promoter marking in all samples but higher H3K27me3 levels at the gene body in 
fresh CD34+ and STFIA- compared to STF-expanded cells (Fig. S10).
Next we hypothesized that employing inhibitors of the histone lysine methyltransferase EZH2 might 
antagonize the elevated H3K27me3 levels of STF- versus STFIA-cultured cells. Treatment of STF-cultured 
CD34+ cells with specific EZH2 inhibitors (GSK343 and GSK12630,31) decreased global H3K27me3 lev-
els comparable to those of CD34+ cells in STFIA culture (Fig.  6B) but did not effect viability or cell 
numbers during expansion (Fig. S11A). Inhibitor treatment of STF cultures did not raise CFU formation 
to levels recorded for fresh or STFIA-expanded cultures (Fig. S11B). To assess the impact of inhibi-
tor treatment on in vivo hematopoietic engraftment potential we transplanted STF-, STFIA-cultured 
and STF-plus inhibitor-cultured CD34+ cells into NSG recipients. We observed that treatment of 
Figure 5. Co-occupancy of H3K4me3 and H3K27me3 on promoters. A) Numbers of promoters marked 
with H3K4me3 and H3K27me3 and numbers of H3K4me3 and H3K27me3 co-occupancy on promoters 
in fresh CD34− and CD34+ cells, and in CD34+ cells expanded for 7 days with either STF or STFIA 
cocktails. B) H3K4me3 and H3K27me3 co-occupancy on promoters and patterns of recurrence and mutual 
exclusion in fresh and cultured cells. Each column represent a gene recorded as bivalent in any of the 4 
samples.
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STF-cultured CD34+ cells with the EZH2 inhibitors increased hematopoietic engraftment at 4 and 12 
weeks post transplantation to levels of STFIA-cultured CD34+ cells engraftment (Fig. 6C). Recipients of 
untreated and treated cells showed multilineage hematopoietic engraftment (Fig. S12).
Discussion
The aim of this study was to provide a better molecular understanding of chromatin changes upon expan-
sion of CB-HPSCs. We observed that globally fresh CD34+ and CD34− cells differed in H3K4me3 and 
H3K27me3 levels and that expansion remodeled the epigenetic landscape of CD34+ cells. Furthermore, 
we noticed that global H3K4me3 and H3K27me3 levels changed depending on culture conditions with 
more changes in H3K27me3- than in H3K4me3-marked regions. Higher protein levels of the PRC2 
Figure 6. Treatment with PRC2 inhibitors and influence on engrafting activity. A) EZH2-specific 
Western blot analysis of fresh CD34− and CD34+ cells, and of CD34+ cells expanded for 7 days with 
either STF or STFIA cocktails. Relative signal intensities of bands were quantified (lower panel). Diagram 
summarizes 3 independent experiments. B) CD34+ cells expanded for 7 days with either STF or STFIA 
cocktails + /− the EZH2 inhibitors GSK343 (1 mM) or GSK126 (1 mM). Intranuclear flow cytometry 
analysis specific for H3K27me3 and H3 of gated CD34+ /CD133+ /CD38− cells. Student t-test, *p < 0.05, 
n = 3. C) After 7 days of culture the progeny of 2 × 105 CD34+ cells in STF- or STFIA-supplemented 
cultures in the absence or presence of either GSK343 or GSK126 EZH2 inhibitors were equally split 
and injected into recipients. Shown are percentages of human chimerism by human CD45-specific flow 
cytometry in the peripheral blood of NSG transplant recipients. Each symbol represents the engraftment of 
a single recipient analyzed 4 and 12 weeks post transplant. All recipients were analyzed and are shown (rec./
cond.: recipients per condition). Student t-test, **p < 0.01, n = 3.
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component EZH2 were detected in STF- compared to STFIA-cultured cells and treatment with EZH2 
inhibitors increased hematopoietic engraftment potential of cultured HPSCs.
As previously reported, we confirmed that STFIA-expanded CD34+ cells engrafted NSG recipients9. 
However, we did not assay the self-renewal potential of engrafted CB-HSCs by secondary transplanta-
tion. In contrast to an earlier report, engraftment levels of STFIA-cultured cells did not reach the 20-fold 
net expansion of repopulating HPSCs9. We also noticed inter-experimental variations in engraftment 
similar to the results reported32. The variable engraftment could arise from a multitude of factors includ-
ing how individual HSCs respond to the growth factors and variability in homing.
As the maintenance of HSC function and the differentiation of HSCs are influenced by epigenetic gene 
regulation12, we aimed at dissecting epigenotype changes between fresh HPSCs and HPSCs expanded 
under different growth factor conditions. Our data of global epigenotypes revealed that H3K4me3 and 
H3K27me3 levels in CD34+ and CD34− cells differ. Similar to an earlier report we noticed higher global 
H3K4me3 levels in fresh CD34+ than in fresh CD34− cells33.
It needs however to be pointed out that human CB CD34+ cells are a heterogeneous cell population 
composed of rare quiescent LT HSCs, cycling short-term HSCs and mostly progenitors. Thus, the data 
collected from this mixed population may overestimate the epigenetic complexity of cell populations 
with similar potentials and that results with highly purified LT-HSCs would differ. Despite these limita-
tions we observed that the H3K27me3 profiles in the HoxA and HoxB loci of fresh and expanded CD34+ 
cells were maintained. On average, a single CB unit allows the collection of about 800,000 CD34+ cells. 
The sample material needed for robust ChIP-seq analyses did not allow the use of higher purified cell 
subsets. Our isolation strategy is in line with selection strategies of related studies17,18,23. To improve the 
situation it is important to further optimize ChIPseq profiling for chromatin amounts obtained from a 
few thousands cells.
Interestingly, culture of HPSCs was paralleled by global changes in H3K27me3 while H3K4me3 lev-
els were less altered. This may indicate that during HPSC expansion PcG-mediated H3K27me3 gene 
silencing seems functionally more relevant to CD34+ cells than the counteracting trxG-mediated gene 
activation.
ChIPseq analyses showed that cultured cells lose H3K27me3 marks at the TSSs and over gene bod-
ies and that the size of H3K4me3-enriched regions increased in cultured cells independent of cytokine 
cocktail. On the other hand, H3K27me3-enriched regions maintained the size distribution of fresh 
CD34+ cells following STFIA expansion. This is reminiscent with the finding in human HPSCs that 
H3K4me3 island size distributions are maintained but that H3K27me3 sizes are increased during dif-
ferentiation18. Also consistent with previous observations is the observation of widespread H3K27me3 
signals that indicate that H3K27me3 occupied broad domains while H3K4me3 signals are confined to 
promoter regions17,34. Our data of variable H3K4me3 and H3K27me3 mark distribution over specific 
gene regions is consistent with observations that H3K4me3 is found promoter-near while the majority 
of H3K27me3 marks occur in intergenic regions and forms broad local enrichments (BLOCs) rather 
than focal peaks17,35.
Stem and mature cells each have distinct epigenomic landscapes and differentiation is paralleled by 
large-scale expansion of H3K27me3 but less H3K4me3 domains34. The H3K27me3 pattern is highly 
variable across different cell types and certain regions such as Hox gene clusters are associated with a 
high-degree of variability36. The H3K4me3 and H3K27me3 landscapes seen at the HoxA or B loci are 
consistent with this notion.
Our analyses further revealed the expected H3K4me3 and H3K27me3 modification profiles around 
the TSSs of highly and lowly expressed genes22. Here we noticed a level of exclusivity of which pro-
moters were H3K4me3- or H3K27me3-marked depending on whether samples from fresh, STF- or 
STFIA-cultured cells were analyzed. The Venn diagrams in Fig.  4A revealed that one third of the 
enriched promoters was unique in individual samples. The exclusively marked promoters of fresh and 
STFIA-expanded CD34+ cells showed similar GO-terms.
Unexpectedly, we observed little transcriptomic changes between STF- and STFIA-cultured cells while 
changes of H3K27me3 and H3K4me3 levels were apparent upon culture. While further studies are clearly 
required, one possibility is that the different cocktails primarily act on the epigenomic and less on tran-
scriptomic regulatory systems. Interestingly transcriptome profiling of mouse ESCs and epiblast stem 
cells, which are naive and primed pluripotent states, reveale small-scale differences in transcriptional 
output but dramatic alterations in chromatin profiles37. This indicates that closely related developmental 
stages are characterized by altered epigenotypes not yet leading to transcriptomic changes.
The altered epigenotypes also indicate that H3K27me3 and H3K4me3 levels of HPSCs are sensitive 
to whether the cells are exposed to in vivo or in vitro environments. This is supported by the observa-
tion of a considerable redistribution of bivalent domains upon culture. Although the total number of 
bivalent promoters was similar in fresh and cultured CD34+ cells, we found approximately two thirds 
of the genes changing between the different conditions. Thus, although transcriptomic changes were 
minor between the STF and STFIA culture conditions, different sets of genes were rendered into a tran-
scriptionally permissive state which later may cause differences in engraftment potential. GO-term anal-
ysis revealed a cocktail-specific reorganization of the bivalency status. The enrichment of blood vessel 
development and morphogenesis terms in STFIA cultures may relate to the activity of Angptls38 or the 
angiogenetic signatures may be relevant for HSC expansion.
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Finally, the results of this study revealed increased culture-induced EZH2 levels probably regulating its 
own expression and leading to elevated H3K27 trimethylation levels in STF- compared to STFIA-cultured 
cells. Therefore, it was obvious to assess if this can be blocked by specific inhibitors. Epigenetic inhibi-
tors have previously been shown to support expansion of CD34+ cells and combination of azaC with 
trichostatin A supports the maintenance of NSG mice repopulating cells20,39. The observation that an 
EZH2 inhibitor treatment counteracted the culture-induced loss of engraftment potential indicates that 
EZH2 activity may be key to the culture-associated loss of engraftment potential.
Following EZH2 inhibition, we noticed differences in vivo but not in in vitro hematopoietic activities. 
This observation may point to an effect of the EZH2 inhibitors on immature HSCs rather than on mature 
progenitor cells. The increased engraftment levels of EZH2 inhibitor-treated cells were not entirely 
unexpected as loss of function mutation of the PRC2 core components Suz12, Eed and EZH2 display 
enhanced hematopoietic progenitor cell activities following transplantation40 and overexpression of EZH2 
preserves HSCs after replicative stress41. Thus, inhibitors of chromatin factors and chromatin-modifying 
agents provide potential strategies for the expansion of HPSCs. Inhibition of histone methyltransferase 
activity by small molecule approaches is an active area of research30.
In summary, we have provide genome-wide maps for H3K4 and H3K27 trimethylation changes upon 
expansion of CB-HPSCs and show that the H3K4me3 but less the H3K27me3 landscape is stable. Our 
data further reveal that inhibition of the PRC2 component EZH2 counteracts the culture-associated loss 
of engraftment potential. These data may lead to new therapeutic tools and rational protocols for robust 
expansion of this clinically important adult stem cell type.
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